features: Movement Disorders
Relaunching the GENERATION HD trial: how will tominersen fare with younger, milder Huntington’s disease patients?
Following the termination of the GENERATION HD1 trial in March 2021, Roche have now announced plans for a new Phase…
AMT-130: the first gene therapy on the horizon for Huntington’s disease?
The first interim data has been published from a Phase I/II trial testing the safety and tolerability of AMT-130. If…
Key themes in Parkinson’s disease research in 2021
Learn more about the major research themes in Parkinson’s disease, discussed at the International Congress of Parkinson’s Disease and Movement…